# Immunovant, Inc. (IMVT)

> Source: Nexqual · https://nexqual.com/IMVT · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Immunovant, Inc. (IMVT), nexqual.com/IMVT" · informational, not investment advice.

**Price:** USD 29.1 (+2.54% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 28.38 · day 27.98–29.12 · 52w 18.51–45.42 · market cap $6.01B · NMS

## Key facts
- 1 of 80 tracked superinvestors hold IMVT (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 2.12 on a 1–5 scale) (17 analysts), mean target USD 48.88 (range 30–66).
- Total return with dividends: 1Y +55.3% vs S&P 500 +14.9%; 5Y +250.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-09, EPS estimate USD -0.72, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Net income | -$157M | -$211M | -$259M | -$414M | -$506M | -$538M |
| EPS (diluted) | -$1.43 | -$1.71 | -$1.88 | -$2.73 | -$2.77 | — |
| Free cash flow | -$106M | -$188M | -$215M | -$377M | -$407M | — |
| Cash + short-term investments | $494M | $377M | $635M | $714M | $902M | — |
Fiscal years end Mar. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 8.2x · Earnings yield -8.95%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold IMVT. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| David Einhorn | Greenlight Capital | 0.09% | $3.6M | Unchanged |

## Analysts
Consensus Buy (mean 2.12 on a 1–5 scale), 17 analysts; mean target USD 48.88 (low 30, high 66).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-04 | JP Morgan | Target raised | Overweight | $47 → $50 |
| 2026-06-30 | Citigroup | Target raised | Buy | $57 → $61 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +55.3% | +250.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +55.5% | +28.4% |
| Volatility (annualized) | 55.6% | 63.1% |
| Max drawdown | -40.5% (Aug 2026→Oct 2026) | -67.2% (Jan 2024→May 2025) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/IMVT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in IMVT's own 10-K filed 2026-05-20 (https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | HanAll Biopharma | "HanAll may disagree with our interpretation of the agreement or our actions thereunder, and we may be unable to reach an agreement with HanAll regarding the future of batoclimab." |
| Partner | Roivant Sciences Ltd. (ROIV) | "On December 19, 2017, Roivant Sciences GmbH ("RSG"), a wholly-owned subsidiary of RSL, entered into a license agreement (the "HanAll Agreement") with HanAll Biopharma Co., Ltd. ("HanAll")." |
| Partner | Leerink Partners | "We have a sales agreement with Leerink Partners LLC ("Leerink Partners"), as sales agent, pursuant to which we may offer and sell, from time to time, shares of our common stock (the "ATM Shares"), subject to certain cond…" |

Other companies that name IMVT in their own reports (relationship from IMVT's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Roivant Sciences Ltd. (ROIV) | 10-K 2026-05-20 | "•the fact that Immunovant relies on a license agreement with HanAll Biopharma Co., Ltd. to provide the rights to the core intellectual property relating to IMVT-1402 and batoclimab;" |

## Company outlook (8-K filed 2026-08-06)

- "The Company expects to provide further updates on its potentially registrational IMVT-1402 D2T RA program and report topline data from the proof-of-concept trial of IMVT-1402 in CLE in the second half of calendar year 2026."
- "In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in GD and MG."
- "Topline data are expected to follow in calendar year 2028 for the potentially registrational trials of IMVT-1402 in CIDP and SjD."
- "Immunovant's expectations regarding the availability of results of clinical trials of IMVT-1402 and whether those results may be adequate to support registration; and the Company's beliefs regarding the potential sufficiency of its cash runway."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.72 | $-0.53 | +37.3% | $0 | 3 |
| Next quarter (ends 2026-12-31) | $-0.67 | $-0.45 | +50.5% | $0 | 3 |
| Current fiscal year (ends 2027-03-31) | $-2.84 | $-2.52 | +12.9% | $0 | 5 |
| Next fiscal year (ends 2028-03-31) | $-2.75 | $-2.40 | +14.7% | $36.8M | 5 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-09): ±13.4%; last 8 reports averaged ±8.3%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 59.3% | ±13.4% |
| 2026-12-18 | 56 | 83.6% | ±26.1% |
| 2027-01-15 | 84 | 79.1% | ±30.0% |
| 2027-03-19 | 147 | 78.5% | ±39.0% |
| 2027-04-16 | 175 | 77.2% | ±41.6% |